SNDL Inc
F:VY4

Watchlist Manager
SNDL Inc Logo
SNDL Inc
F:VY4
Watchlist
Price: 1.91 EUR 0.79% Market Closed
Market Cap: 504.8m EUR
Have any thoughts about
SNDL Inc?
Write Note

Relative Value

The Relative Value of one VY4 stock under the Base Case scenario is 2.15 EUR. Compared to the current market price of 1.91 EUR, SNDL Inc is Undervalued by 11%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VY4 Relative Value
Base Case
2.15 EUR
Undervaluation 11%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
76
Median 3Y
0.9
Median 5Y
1.4
Industry
2.5
Forward
0.8
vs History
vs Industry
Median 3Y
-4.6
Median 5Y
-3.1
Industry
21.9
Forward
-16.5
vs History
7
vs Industry
21
Median 3Y
-10.5
Median 5Y
-9.8
Industry
16.5
vs History
vs Industry
Median 3Y
-8.9
Median 5Y
-7.7
Industry
23.6
vs History
53
vs Industry
72
Median 3Y
0.6
Median 5Y
0.7
Industry
2.1
vs History
79
vs Industry
79
Median 3Y
0.8
Median 5Y
1.7
Industry
2.6
Forward
0.6
vs History
80
vs Industry
61
Median 3Y
3.3
Median 5Y
8.8
Industry
5.2
vs History
20
vs Industry
4
Median 3Y
-16.2
Median 5Y
-11.3
Industry
13.3
Forward
22.4
vs History
vs Industry
Median 3Y
-12.3
Median 5Y
-11.1
Industry
16.6
Forward
-50.8
vs History
7
vs Industry
23
Median 3Y
-8.7
Median 5Y
-6.4
Industry
15.6
vs History
7
vs Industry
18
Median 3Y
-8.2
Median 5Y
-5.8
Industry
19.1
vs History
52
vs Industry
73
Median 3Y
0.5
Median 5Y
0.5
Industry
1.9

Multiples Across Competitors

VY4 Competitors Multiples
SNDL Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CA
SNDL Inc
F:VY4
506.9m EUR 0.8 -6.7 39 -13.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
710.5B USD 17.4 84.9 45.7 51
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.3T DKK 12.3 35 24.3 27.8
US
Johnson & Johnson
NYSE:JNJ
373.5B USD 4.3 25.4 12.3 16
US
Merck & Co Inc
NYSE:MRK
251.1B USD 4 20.7 10.5 12.5
CH
Roche Holding AG
SIX:ROG
202.7B CHF 3.5 17.6 9.9 11.8
CH
Novartis AG
SIX:NOVN
183.3B CHF 4.1 11.6 10.1 14
UK
AstraZeneca PLC
LSE:AZN
162.4B GBP 4.1 31.6 169.4 253.9
IE
Endo International PLC
LSE:0Y5F
146B USD 63 -49.9 234.4 587.7
P/E Multiple
Earnings Growth
CA
SNDL Inc
F:VY4
Average P/E: 32.4
Negative Multiple: -6.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
84.9
451%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
35
86%
US
Johnson & Johnson
NYSE:JNJ
25.4
-22%
US
Merck & Co Inc
NYSE:MRK
20.7
7 321%
CH
Roche Holding AG
SIX:ROG
17.6
32%
CH
Novartis AG
SIX:NOVN
11.6
21%
UK
AstraZeneca PLC
LSE:AZN
31.6
177%
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -49.9 N/A
EV/EBIT Multiple
EBIT Growth
CA
SNDL Inc
F:VY4
Average EV/EBIT: 2 075.2
Negative Multiple: -13.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
51
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
27.8
85%
US
Johnson & Johnson
NYSE:JNJ
16
29%
US
Merck & Co Inc
NYSE:MRK
12.5
695%
CH
Roche Holding AG
SIX:ROG
11.8
27%
CH
Novartis AG
SIX:NOVN
14
54%
UK
AstraZeneca PLC
LSE:AZN
253.9
131%
IE
E
Endo International PLC
LSE:0Y5F
587.7
N/A

See Also

Discover More
Back to Top